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Biocatalytic self-assembly (BSA) emerged as selective and eﬀective approach for cancer therapy. BSA makes use
of enzyme-sensitive moiety that is incorporated in an amphiphilic molecule (usually peptide amphiphile, PA). This
unit is transfomred/removed upon enzymatic action causing rebalance of the molecule’s amphiphilicity and self-
assembling ability. Among diﬀerent enzymes, phosphatases (e.g. alkaline phosphatase, ALP) are the best studied
ones for BSA targeting cancer. Recently, we describe a simple carbohydrate amphiphile (CA) as an alternative of
PA and demonstrated its potential for treatment of osteosarcoma using BSA. Herein, we discuss another
advantage of CAs in cancer therapy: they can act as antagonists of the glucose transporters (GLUTs) due to their
structural similarity with glucose. Cancer cells have an accelerated metabolism, which requires high consumption
of glucose. As a result, they overexpressed GLUTs, particularly GLUT1 and GLUT3. We studied several cancer cell
lines overexpressing GLUTs and demonstrate that indeed the presence of CAs alter the glucose transport: a
competitive assay showed that CAs reduced signiﬁcantly the uptake of glucose, suggesting a possible blocking of
GLUTs and glycolysis. Cancer cells cultured in the presence of CAs also showed a decrease in cell proliferation,
metabolic activity and activation of an apoptotic pathway, that ultimately led to cell death. We conclude that the
selective apoptosis of cancer cells is based on two synergistic mechanisms: formation of pericellular net that traps
selectively the phosphatase overexpressing cells and blockage of glucose transport in these cells. 

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Glucose uptake blocked in the presence of the CA in the cancer cell line SaOs2. CA: Cabrohydrate amphiphile;
NBDG: Fluorescent labeled Glucose
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